The biopharmaceutical industry clearly isn’t going anywhere, but we’ve been in a downward business cycle. We've learned a lot from the pandemic and have adopted novel approaches to development and this current economic challenge will also inform us. In the meantime, adopting these strategies can de-risk your development programs.
It's not enough for a healthcare startup to just have cool technology. To get buy-in from investors, entrepreneurs have to showcase some healthcare economics chops, as well as a solid business model and reimbursement plan.
How to turn analytics into actual policy outcomes.
Over the course of three days at the Mayo Clinic‘s annual Transform conference, featuring scores of healthcare’s top names, several themes stood out. Here’s what I gather were the main points. 1. Economic factors and barriers are just as important in determining health outcomes for the population as a whole. It stands to reason – […]
Specialty drugs – the costly medications used to treat complex disease like cancer and Hepatitis C – have become a hot-button topic given the fact that healthcare spending is perpetually on the rise. After a five-year contraction in healthcare spending growth, medical costs are projected to climb another 6.8 percent in 2015, according to the Health […]